Rate My Professor Simon Royce

Dr. Simon G. Royce is a Senior Research Fellow in the Department of Pharmacology at Monash University, within the Faculty of Medicine, Nursing and Health Sciences, and is affiliated with the Victorian Heart Institute. He earned his Bachelor of Science with Honours (B.Sc. Hons) and Doctor of Philosophy (Ph.D.) in Pathology from the University of Melbourne. Royce's research specializes in the pharmacology of chronic lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), and silicosis. His investigations focus on anti-fibrotic mechanisms, bronchodilator targets, and novel therapeutic interventions for airway fibrosis and lung damage.

Royce contributes to multiple funded projects, such as establishing non-invasive screening for early detection of silicosis (2023-2025), developing a novel human model for anti-fibrotic drug screening in silicosis funded by iCare NSW (2023-2026), blocking harmful lung damage during acute COPD exacerbations (2023-2025), and exploring free fatty acid receptors as bronchodilator targets in severe asthma (NHMRC-funded, 2020-2022). He has supervised doctoral students including Dr. Hamish Philpott, Dr. Krupesh Patel, Dr. Maggie Lam, Dr. Vivian Mao, Dr. Amlan Chakraborty, Ms. Claudia Sim, and Mr. Mahesh Dharmakumara. His key publications encompass 'Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms' (2022, Cellular and Molecular Life Sciences), 'Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease' (2015, Stem Cell Research & Therapy), 'Serelaxin improves the therapeutic efficacy of RXFP1-expressing mesenchymal stem cells in experimental pulmonary fibrosis' (2019, British Journal of Pharmacology), 'The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21' (2025, Clinical Science), and 'Human bone marrow mesenchymal stem cell-derived extracellular vesicles induce inverse dose-dependent anti-fibrotic effects' (2025, Biomedicine & Pharmacotherapy). Royce co-holds US Patent 11471493 for the method using induced pluripotent stem cell-derived mesenchymal stem cells to treat asthma. His research supports SDG 3: Good Health and Well-being and has garnered over 4,300 citations.